Virtual Library

Start Your Search

Narayana Subramaniam



Author of

  • +

    Mini Oral session III (ID 65)

    • Event: ELCC 2019
    • Type: Mini Oral session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/12/2019, 17:45 - 18:45, Room C
    • +

      120O - Thromboembolic events in advanced non-small cell lung cancer (ID 312)

      17:45 - 18:45  |  Author(s): Narayana Subramaniam

      • Abstract
      • Presentation
      • Slides

      Background

      Cancer is a prothrombotic condition and its treatment is often complicated in the presence of thromboembolisms (TE) which adds to its morbidity and mortality. We aimed to assess the incidence of TE’s in patients with NSCLC treated at our institute.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A retrospective observational study of patients with NSCLC treated between January 2011 and December 2016 were included. Time of onset of TE’s either at diagnosis or after the start of platinum-based chemotherapy was noted, Khorana score was calculated in all patients with TE’s. A TE occurring between first dose of chemotherapy and 4 weeks after the last dose was considered to be chemotherapy associated.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      On analysis of records from the EMR, we found a total of 1542 NSCLC patients who were treated at our institute, with a male to female ratio of 3.5 : 1. All patients with TE’s had stage IV disease at the time of presentation. Fifty-nine (3.8%) patients out of 1542 developed TE’s, 53 had venous TE and 6 had cerebral arterial infarction. Twenty-five (1.6%) had TE’s at the time of diagnosis while 34 (2.9%) out of 1180 developed TE while on treatment with platinum based chemotherapy. The mean age was 60 years (Range:34-81 yrs) with a male predominance (59%). Majority of patients developed TE’s within 100 days from the start of chemotherapy with a median time of 66 days. (Range:14-143 days) Intermediate and high risk groups on assessment of Khorana score was 61% and 39% respectively. The median overall survival for patients with TE was 129 days in comparison to 234 days for patients without thromboembolisms.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Thromboembolism is associated with a poor prognosis in patients with advanced lung cancer. Patients receiving platinum-based chemotherapy are predisposed to higher incidences of thromboembolic events which raises a valid question of the need of thromboprophylaxis in a selected group of patients.

      b651e8a99c4375feb982b7c2cad376e9 Clinical trial identification

      It is not a clinical trial

      7a6a3ffa2dadc03a6151ee2c4d6fa383 Legal entity responsible for the study

      Amrita Institute of Medical Science.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.